MENU
+Compare
HALO
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$74.93
Change
+$1.53 (+2.08%)
Capitalization
8.76B

HALO Halozyme Therapeutics Forecast, Technical & Fundamental Analysis

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more

Industry: #Biotechnology
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HALO with price predictions
Sep 05, 2025

HALO in +2.28% Uptrend, growing for three consecutive days on September 03, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for HALO moved above the 200-day moving average on August 06, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 295 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

HALO broke above its upper Bollinger Band on August 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.316) is normal, around the industry mean (20.143). P/E Ratio (17.146) is within average values for comparable stocks, (52.852). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.088). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (8.110) is also within normal values, averaging (327.233).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

HALO is expected to report earnings to rise 3.25% to $1.59 per share on November 10

Halozyme Therapeutics HALO Stock Earnings Reports
Q3'25
Est.
$1.59
Q2'25
Beat
by $0.30
Q1'25
Beat
by $0.13
Q4'24
Beat
by $0.11
Q3'24
Beat
by $0.31
The last earnings report on August 05 showed earnings per share of $1.54, beating the estimate of $1.24. With 1.89M shares outstanding, the current market capitalization sits at 8.76B.
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NUW13.940.20
+1.46%
Nuveen AMT-Free Municipal Value Fund
BUFS22.190.08
+0.35%
FT Vest Laddered Small Cap Moderate Buffer ETF
PJUL45.05N/A
N/A
Innovator U.S. Equity Power BffrETF™-Jul
AGIH25.01N/A
N/A
iShares Inflation Hedged US Aggregate
FXC70.55-0.12
-0.17%
Invesco CurrencyShares® Canadian Dollar

HALO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with XENE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
+2.08%
XENE - HALO
45%
Loosely correlated
+1.48%
IRON - HALO
37%
Loosely correlated
+0.95%
IDYA - HALO
35%
Loosely correlated
+5.15%
NGNE - HALO
35%
Loosely correlated
+1.73%
TECH - HALO
35%
Loosely correlated
+2.82%
More